Steris Plc Stock Price, News & Analysis

Mettler-Toledo (NYSE: MTD) announced that Michael J. Tokich will join its Board of Directors, effective February 5, 2026. Mr. Tokich served more than 17 years as Senior Vice President and Chief Financial Officer at STERIS and recently transitioned to Senior Financial Advisor at STERIS. He joined STERIS in 2000 and became CFO in 2008. Board Chair Roland Diggelmann highlighted Tokich’s nearly two decades of U.S. public company CFO experience and said his financial, operational, and IT expertise will add value to Mettler-Toledo’s oversight. The company reiterated its global leadership in precision instruments and broad sales and service network across approximately 40 direct-presence countries.

STERIS (NYSE: STE) reported fiscal 2026 second quarter results: total revenue $1.5B (+10% YoY) and constant-currency organic revenue +9%. As-reported EPS from continuing operations was $1.94; adjusted EPS $2.47 vs $2.14 year-ago. Segment performance: Healthcare revenue $1,033.8M (+9%), AST $281.5M (+10%) with a 76% decline in capital equipment, and Life Sciences $145.0M (+13%).

Cash: H1 operating cash $707.8M and free cash flow $527.7M (H1). Company raised fiscal 2026 guidance: constant-currency organic revenue now +7–8%, adjusted EPS $10.15–10.30, and free cash flow ~ $850M; tariffs still estimated to cut pre-tax profit by ~$45M and effective tax rate ~24%.

STERIS (NYSE: STE) announced a quarterly cash dividend of $0.63 per share, payable on December 18, 2025 to shareholders of record as of November 18, 2025. The company noted U.S. tax-treatment information and Forms 8937 are available on its investor website.

The release reiterates forward-looking cautionary language about risks that could affect future results, including operating costs, integration of acquisitions, litigation, and macroeconomic factors.

STERIS (NYSE: STE) will host a conference call to discuss its fiscal 2026 second quarter results at 9:00 a.m. ET on November 6, 2025. A press release with financial results will be issued after the U.S. market close on November 5, 2025. The live call is available at www.steris-ir.com or by phone (US: 1-800-715-9871; international: 1-646-307-1963). A replay will be available beginning 12:00 p.m. ET on November 6, 2025 via the investor site or by phone using access code 2170300 (US replay: 1-877-344-7529; international replay: 1-412-317-0088).

STERIS plc (NYSE: STE) announced a significant leadership transition as long-time Chief Financial Officer Michael J. Tokich steps down after 17 years in the role. Karen L. Burton, currently Vice President and Chief Accounting Officer, will succeed Tokich as Senior Vice President and CFO effective August 18, 2025.

Under Tokich's tenure as CFO since 2008, STERIS has experienced remarkable growth, with revenue quadrupling and market capitalization increasing from $1 billion to $22 billion. Tokich will transition to the role of Senior Financial Advisor, reporting to the CEO. Burton, who has been with STERIS since 2004 and served as CAO since 2017, will oversee all global finance functions and IT in her new role.

STERIS plc (NYSE: STE) reported strong fiscal 2026 first quarter results, with total revenue increasing 9% to $1.4 billion and constant currency organic revenue growing 8%. The company's net income from continuing operations reached $177.4 million, or $1.79 per diluted share, while adjusted EPS grew to $2.34.

Performance was driven by growth across all segments: Healthcare revenue grew 8% to $974.7 million, Applied Sterilization Technologies increased 13% to $281.2 million, and Life Sciences rose 5% to $135.2 million. Free cash flow significantly improved to $326.5 million.

STERIS updated its fiscal 2026 outlook, raising revenue growth expectations to 8-9% from 6-7%, while maintaining adjusted EPS guidance of $9.90-$10.15. The company now expects free cash flow of approximately $820 million, up from previous guidance of $770 million.

STERIS (NYSE: STE) has announced a quarterly dividend increase to $0.63 per share, marking a $0.06 increase from the previous dividend. This represents the company's 20th consecutive year of dividend growth. The dividend will be payable on September 26, 2025, to shareholders of record as of September 4, 2025.

STERIS, a leading global provider of products and services supporting patient care with a focus on infection prevention, continues to demonstrate its commitment to shareholder returns through consistent dividend growth. The company helps create a healthier and safer world by providing innovative healthcare and life science solutions globally.

STERIS (NYSE: STE) has scheduled a conference call to discuss its fiscal 2026 first quarter results on August 7, 2025, at 9:00 a.m. ET. The company will release its financial results after market close on August 6, 2025.

Investors can access the call through www.steris-ir.com or by phone using specific dial-in numbers for U.S. (1-833-535-2199) and international (1-412-902-6776) participants. A replay will be available from 12:00 p.m. ET on August 7, using access code 2889488.

STERIS (NYSE: STE) reported strong financial results for fiscal 2025, with full-year revenue from continuing operations increasing 6% to $5.5 billion. The company's fourth quarter revenue grew 4% to $1.5 billion, with constant currency organic revenue growth of 6%. Full-year net income reached $610.1 million, or $6.16 per diluted share, while adjusted EPS increased to $9.22.

Healthcare segment revenue grew 5% to $1.1 billion in Q4, while Applied Sterilization Technologies (AST) revenue increased 9% to $273.9 million. Life Sciences revenue decreased 7% to $149.5 million. The company generated strong free cash flow of $787.2 million for fiscal 2025.

For fiscal 2026, STERIS expects 6-7% revenue growth and adjusted EPS of $9.90-$10.15, despite an estimated $30 million negative impact from tariffs.